참고문헌
- Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789. https://doi.org/10.1001/jama.290.6.781
- Freedman M, Kroger A, Hunter P, Ault KA; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2020. Ann Intern Med 2020;172:337-347. https://doi.org/10.7326/M20-0046
- Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63(RR-05):1-30.
- Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al.; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-723. https://doi.org/10.1056/NEJMoa1405044
- GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-1985. https://doi.org/10.1016/S0140-6736(09)61567-1
- Oshman LD, Davis AM. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). JAMA 2020;323:468-469. https://doi.org/10.1001/jama.2019.18411
- Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al.; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64:300-304.
- Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States [Internet]. Atlanta (GA): National Center for Immunization and Respiratory Diseases; 2021 [updated 2021 Mar 5; cited 2021 Apr 5]. Available from: https://www.cdc.gov/vaccines/covid-19/info-byproduct/clinical-considerations.html.
- Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-192. https://doi.org/10.1016/S1473-3099(20)30843-4